Asian Journal of Research in Pharmaceutical Sciences

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Pharmacological Review on Tobramycin


Affiliations
1 Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India
     

   Subscribe/Renew Journal


Tobramycin is another aminoglycoside anti-microbial with a wide antibacterial range in vitro, and pharmacokinetic properties like those for gentamicin. Tobramycin is more dynamic than gentamicin against Pseudomonas aeruginosa and dynamic against numerous gentamicin safe strains, yet isn't dynamic against enterobacteriaceae impervious to gentamicin. Hypothetically, tobramycin enjoys an upper hand over gentamicin against diseases brought about by P. aeruginosa, yet any benefit in clinical practice presently can't seem to be enough illustrated. Clinical involvement in tobramycin is significantly not exactly with gentamicin. While tobramycin seems to offer no unmistakable benefits over gentamicin against touchy organic entities it is shown in contamination brought about by strains of P. aeruginosa which are impervious to gentamicin, yet touchy to tobramycin. Like gentamicin, tobramycin acts synergistically with carbenicillin and the cephalosporins. The viability of the tobramycin-carbenicillin blend has been displayed in endocarditis brought about by P. aeruginosa which was lethargic to gentamicin in addition to carbenicillin. Ototoxicity and nephrotoxicity like that seen with other aminoglycosides have been experienced in helpful preliminaries with tobramycin and more extensive clinical experience is important to decide the general occurrence of these incidental effects with gentamicin and tobramycin utilized under comparable conditions. Antimicrobial movement: In relative examinations, in vitro, tobramycin is more dynamic than gentamicin against clinical separates of Pseudomonas aeruginosa. Likewise, the inhibitory file, which is the proportion between the serum fixations accomplished at common remedial portions and the base inhibitory focus, for Pseudomonas aeruginosa is higher for tobramycin than for gentamicin.

Keywords

Antibiotic, Tobramycin, Aminoglycoside, Anti-microbial, Pseudomonas aeruginosa
Subscription Login to verify subscription
User
Notifications
Font Size


  • Abbas HA, Serry FM, El-Masry EM. Non-steroidal anti-inflammatory drugs and sodium ascorbate potentiate the antibiotic activity against Pseudomonas aeruginosa biofilms. Research Journal of Pharmacy and Technology. 2012; 5(8):1124-9.

  • Malviya V. Preparation and Evaluation of Emulsomes as a Drug Delivery System for Bifonazole. Indian Journal of Pharmaceutical Education and Research. 2021 Jan 1;55(1):86-94.

  • Abbas HA, Serry FM, EL-Masry EM. N-acetylcysteine and Ambroxol: can mucolytics dissolve the resistance of biofilms to antibiotics. Research Journal of Pharmacy and Technology. 2012;5(7):912-7.

  • Malviya VR, Pande SD, Bobade NN. Preparation and Evaluation of Sustained Release Beads of Zolmitriptan Hydrochloride. Research Journal of Pharmacy and Technology. 2019;12(12):5972-6.

  • Abbas HA, Serry FM, EL-Masry EM. Biofilms: The microbial castle of resistance. Research Journal of Pharmacy and Technology. 2013;6(1):1-3.

  • Abbas HA, El-Saysed MA, Ganiny AM, Fattah AA. Antimicrobial Resistance Patterns of Proteus mirabilis isolates from Urinary tract, burn wound and Diabetic foot Infections. Research Journal of Pharmacy and Technology. 2018;11(1):249-52.

  • Al-Faqeeh LA, Naser R, Kagne SR. Determination of antibiotic resistant profiles for bacteria isolated from clinical samples in Aurangabad, India. Research Journal of Pharmacy and Technology. 2020;13(8):3813-6.

  • Al-Oqaili NA, Al-Shebli MK, Almousawi AN. Molecular Characterizations of Aminoglycoside Modifying Enzymes of Proteus mirabilis Isolated From Patients in Al-Qadisiyah Governorate. Research Journal of Pharmacy and Technology. 2018;11(7):2809-13.

  • Malviya V, Thakur Y, Gudadhe SS, Tawar M. Formulation and evaluation of natural gum based fast dissolving tablet of Meclizine hydrochloride by using 3 factorial design 2. Asian Journal of Pharmacy and Pharmacology. 2020;6(2):94-100.

  • Rana S, Sirwar SB. Prevalence and Antibiogram of Extended Spectrum β-Lactamase Producing Klebsiella pneumoniae and Proteus mirabilis in UTI. Research Journal of Pharmacy and Technology. 2015;8(11):1465-8.

  • Malviya V, Ladhake V, Gajbiye K, Satao J, Tawar M. Design and Characterization of Phase Transition System of Zolmitriptan Hydrochloride for Nasal Drug Delivery System. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 May 31;13(3):4942-51.

  • Malviya VR, Tawar MG. Preparation and Evaluation of Oral Dispersible Strips of Teneligliptin Hydrobromide for Treatment of Diabetes Mellitus. International Journal of Pharmaceutical Sciences and Nanotechnology. 2020 Jan 31;13(1):4745-52.

  • Rao US, Khamsah SM, Atif AB, Latif AZ. Scopoletin (Coumarin extracted from Mengkudu): Chemical, Biological, Molecular and Pharmacokinetic insights–A Review. Research Journal of Pharmacy and Technology. 2013;6(9):978-84.

  • Malviya V, Manekar S. Design, Development and Evaluation of Aceclofenac and Curcumin Agglomerates by Crystallo Co-Agglomeration Technique. Research Journal of Pharmacy and Technology. 2021 Mar 18;14(3):1535-41.

  • Malviya VR, Pande SD. Road CKN. Preparation ad Evaluation of Zolmitriptan Hydrochloride Lozenge. J Pharma Res. 2019;8(8):624-9.

  • Neu HC. Tobramycin: an overview. The Journal of infectious diseases. 1976 Aug 1:S3-19.

  • Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev-K M, Borowitz D, Bowman CM, Marshall BC, Marshall S. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. New England Journal of Medicine. 1999 Jan 7;340(1):23-30.

  • Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, Schidlow DV, Wilmott RW, Astley SJ, McBurnie MA, Wentz K. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. New England Journal of Medicine. 1993 Jun 17;328(24):1740-6.

  • Nichols WW, Dorrington SM, Slack MP, Walmsley HL. Inhibition of tobramycin diffusion by binding to alginate. Antimicrobial agents and chemotherapy. 1988 Apr;32(4):518-23.

  • Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI®). Drugs. 2003 Nov;63(22):2501-20.

  • Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002 Jul 1;122(1):219-26.

  • Burke DA, Axon AT, Clayden SA, Dixon MF, Johnston D, Lacey RW. The efficacy of tobramycin in the treatment of ulcerative colitis. Alimentary pharmacology & therapeutics. 1990 Apr;4(2):123-9.

  • Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002 Jul 1;122(1):219-26.

  • Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrobial agents and chemotherapy. 1985 Apr;27(4):619-24.

  • Nickel JC, Ruseska I, Wright JB, Costerton JW. Tobramycin resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrobial agents and chemotherapy. 1985 Apr;27(4):619-24.

  • Domalaon R, Ammeter D, Brizuela M, Gorityala BK, Zhanel GG, Schweizer F. Repurposed antimicrobial combination therapy: Tobramycin-ciprofloxacin hybrid augments activity of the anticancer drug mitomycin C against multidrug-resistant Gram-negative bacteria. Frontiers in microbiology. 2019 Jul 10;10:1556.

  • Rampogu S, Lee KW. Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics. Frontiers in Chemistry. 2021;9.

  • Maiden MM, Zachos MP, Waters CM. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential. Journal of Antimicrobial Chemotherapy. 2019 Apr 1;74(4):894-906.

  • Ahmed MZ, Zia Q, Haque A, Alqahtani AS, Almarfadi OM, Banawas S, Alqahtani MS, Ameta KL, Haque S. FDA-approved antiviral and anti-infection agents as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study. Journal of Infection and Public Health. 2021 Feb 9.

  • Burange PJ, Tawar MG, Bairagi RA, Malviya VR, Sahu VK, Shewatkar SN, Sawarkar RA, Mamurkar RR. Synthesis of silver nanoparticles by using Aloe vera and Thuja orientalis leaves extract and their biological activity: a comprehensive review. Bulletin of the National Research Centre. 2021 Dec;45(1):1-3.


Abstract Views: 127

PDF Views: 0




  • Pharmacological Review on Tobramycin

Abstract Views: 127  |  PDF Views: 0

Authors

Rahul Jodh
Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India
Mukund Tawar
Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India
Aparna Kachewar
Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India
Yogiraj Ingole
Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India
Tejas Deshmukh
Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India
Vipul Ijapure
Department of Pharmacology, P.R. Pote Patil College of Pharmacy, Amravati., India

Abstract


Tobramycin is another aminoglycoside anti-microbial with a wide antibacterial range in vitro, and pharmacokinetic properties like those for gentamicin. Tobramycin is more dynamic than gentamicin against Pseudomonas aeruginosa and dynamic against numerous gentamicin safe strains, yet isn't dynamic against enterobacteriaceae impervious to gentamicin. Hypothetically, tobramycin enjoys an upper hand over gentamicin against diseases brought about by P. aeruginosa, yet any benefit in clinical practice presently can't seem to be enough illustrated. Clinical involvement in tobramycin is significantly not exactly with gentamicin. While tobramycin seems to offer no unmistakable benefits over gentamicin against touchy organic entities it is shown in contamination brought about by strains of P. aeruginosa which are impervious to gentamicin, yet touchy to tobramycin. Like gentamicin, tobramycin acts synergistically with carbenicillin and the cephalosporins. The viability of the tobramycin-carbenicillin blend has been displayed in endocarditis brought about by P. aeruginosa which was lethargic to gentamicin in addition to carbenicillin. Ototoxicity and nephrotoxicity like that seen with other aminoglycosides have been experienced in helpful preliminaries with tobramycin and more extensive clinical experience is important to decide the general occurrence of these incidental effects with gentamicin and tobramycin utilized under comparable conditions. Antimicrobial movement: In relative examinations, in vitro, tobramycin is more dynamic than gentamicin against clinical separates of Pseudomonas aeruginosa. Likewise, the inhibitory file, which is the proportion between the serum fixations accomplished at common remedial portions and the base inhibitory focus, for Pseudomonas aeruginosa is higher for tobramycin than for gentamicin.

Keywords


Antibiotic, Tobramycin, Aminoglycoside, Anti-microbial, Pseudomonas aeruginosa

References